Lexeo Therapeutics shares rose 24% to $3.55 in premarket trading Monday after the company reported interim results from a trial of LX2020, its treatment for PKP2 arrhythmogenic cardiomyopathy. The gain came after the stock had fallen 71% this year through Friday’s close.
Data from ten participants in the ongoing Phase I/II clinical trial showed LX2020 was generally well tolerated, Lexeo said. The company also reported clinically meaningful reductions in non-sustained ventricular tachycardia and premature ventricular contractions, alongside improvement in measures of right ventricular function and in patient-reported symptoms.
“The magnitude and consistency of NSVT reduction far exceed what available therapies have historically achieved,” Chief Executive R. Nolan Townsend said. Lexeo said it is designing a study that would use NSVT as a primary surrogate endpoint to support a potential accelerated approval.
Mutations in the PKP2 gene are the most common genetic cause of arrhythmogenic cardiomyopathy, accounting for about 50% of cases and affecting an estimated 60,000 people in the U.S., according to Lexeo. The company said PKP2 deficiency can lead to myocardial cell death, fibrosis, heart dysfunction, rhythm abnormalities and sudden cardiac death.
Lexeo also reported Monday that its third-quarter loss was larger than a year earlier and wider than FactSet analysts had expected.
Comments (0)
No comments yet. Be the first!